YK-029A

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameYK-029A
Drug Alias NameYK-029AYK-209AYK-209-AYK-029-A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR exon 20 insertion mutations
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHainan Yuekang Biomedicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Puhe Pharmaceutical Technology Co LtdHainan Yuekang Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsDrug-Related Side Effects and Adverse ReactionsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A